Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Proteins & Peptides
Filter     Order     Display # 
Date Item Title Hits
17 Mar 2010 CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin 15
17 Mar 2010 Cytheris Announces Publication of Preclinical Study in Journal of Immunology Showing Interleukin-7 Promotes T Cell Viability, Trafficking, and Functionality While Improving Survival in Sepsis 17
17 Mar 2010 Protalix Initiates a Phase I Clinical Trial of Acetylcholinesterase for Biodefense Indications 15
16 Mar 2010 Desmoteplase enters clinical phase II in Japan in ischaemic stroke representing Lundbeck's first clinical programme in Japan 34
16 Mar 2010 Viron Reports Positive Proof of Concept Results in Arthritis for its VT-346 anti-TNF Therapeutic 37
16 Mar 2010 Spinal Restoration Initiates Patient Enrollment for Phase III Study of Company's Biostat System 34
15 Mar 2010 Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission 46
15 Mar 2010 FDA Requests Additional Information Regarding AFREZZA(TM) in Complete Response Letter to MannKind 22
15 Mar 2010 Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy 28
12 Mar 2010 Ipsen Grants Rhythm Exclusive Worldwide License 53
11 Mar 2010 Allon's Phase 1 Trial Broadens Davunetide's Intranasal Safety and Dose Range 61
11 Mar 2010 FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 47
11 Mar 2010 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 41
11 Mar 2010 ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps(TM) and Appoints New Chief Medical Officer 37
10 Mar 2010 BOTOX (OnabotulinumtoxinA) Receives FDA Approval for Treatment of Upper Limb Spasticity in Adults 68
09 Mar 2010 BioMimetic Therapeutics Presents Promising Pre-Clinical Sports Medicine Data at the 2010 ORS Meeting 64
08 Mar 2010 Acologix Presents Data on Cartilage Regeneration by AC-100 at the 56th Annual Meeting of the Orthopaedic Research Society 99
04 Mar 2010 Raptor Pharmaceutical Announces Publication of Data Supporting Potential Efficacy of WntTide(TM) in Treatment of Triple-Negative Breast Cancer 73
03 Mar 2010 Novo Nordisk receives FDA approval for Norditropin FlexPro for growth hormone treatment (3 March 2010) 100
02 Mar 2010 Zealand Pharma and PolyTherics enter Collaboration Agreement for novel optimised biopharmaceuticals 68
02 Mar 2010 Capstone Therapeutics Announces Continuation of AZX100 Phase 2 Clinical Trial in Keloid Scarring 51
01 Mar 2010 FDA Accepts VIAject(R) NDA for Review 88
26 Feb 2010 Agennix AG Announces Longer-Term Mortality Results From Talactoferrin Phase 2 Trial in Severe Sepsis 72
26 Feb 2010 Shire Announces FDA Approval of VPRIV™ (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 78
25 Feb 2010 Data from a post hoc analysis using desmoteplase in ischaemic stroke presented at the International Stroke Conference 80
25 Feb 2010 Copaxone® 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety 130
24 Feb 2010 Lorus Announces Publication Demonstrating Antitumor Efficacy of Interleukin 17E 63
24 Feb 2010 Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL® (agalsidase alfa) with the U.S. Food and Drug Administration (FDA) 69
24 Feb 2010 Pantec Biosolutions reports successful Phase I for delivery of FSH using P.L.E.A.S.E.® 98
23 Feb 2010 Allon Presents Peripheral Neuropathy Preclinical Efficacy Data For AL-309 66
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 2051

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

Oncology Market Leaders
Order Now

Subscribe La Merie Biologics